Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Tuberculosis

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 49 articles: HTML format

Single Articles

August 2025
1. SCOPAZZINI M, Zenner D
   Tuberculosis preventive treatment in people living with HIV: to improve treatment completion, we need a simpler cascade of care.
   Eur Respir J. 2025;66:2500638.
   PubMed    
   
   
   
2. LANGE C, Barry C 3rd, Sotgiu G
   Linezolid for the treatment of drug-resistant tuberculosis.
   Eur Respir J. 2025;66:2500927.
   PubMed    
   
   
   July 2025
3. KWAK N, Kim JY, Han A, Berry C, et al
   Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: An individual patient data meta-analysis.
   Eur Respir J. 2025 Jul 17:2500315. doi: 10.1183/13993003.00315-2025.
   PubMed     Abstract available
   
   
   
4. ORDONEZ AA, Willy Vangu MD, Rajaratnam A, Mofokeng N, et al
   Collagen-targeted PET/CT Imaging of Tuberculosis Patients.
   Eur Respir J. 2025 Jul 10:2500195. doi: 10.1183/13993003.00195-2025.
   PubMed    
   
   
   
5. DUPUIS GN, Dolynska M, Chiang SS, Horsburgh CR Jr, et al
   Risk of rifampin resistance emergence after incomplete first-line tuberculosis treatment.
   Eur Respir J. 2025 Jul 3:2500902. doi: 10.1183/13993003.00902-2025.
   PubMed    
   
   
   
6. MIGLIORI GB, Centis R, D'Ambrosio L, Rossato Silva D, et al
   Post Tuberculosis Lung Disease: questions and answers.
   Eur Respir J. 2025 Jul 3:2500992. doi: 10.1183/13993003.00992-2025.
   PubMed    
   
   
   
7. ZENNER D, Haghparast-Bidgoli H, Chaudhry T, Abubakar I, et al
   How to diagnose TB in migrants? A systematic review of reviews and decision tree analytical modelling exercise to evaluate properties for single and combined tuberculosis screening tests.
   Eur Respir J. 2025;66:2402000.
   PubMed     Abstract available
   
   
   June 2025
8. TEO AKJ, Luu KB, Garden F, Pham CD, et al
   The relationship between a known diagnosis of tuberculosis and symptom reporting: implications for case detection strategies.
   Eur Respir J. 2025 Jun 26:2402521. doi: 10.1183/13993003.02521-2024.
   PubMed    
   
   
   
9. AKKERMAN OW, Falzon D, Migliori GB, Konstantynovska O, et al
   WHO online guide on the use of digital technologies for tuberculosis programmes.
   Eur Respir J. 2025;65:2401126.
   PubMed    
   
   
   May 2025
10. DEGTYAREVA S, Hamada Y, Baggaley RF, Hassan N, et al
    Tuberculosis Preventive Treatment care pathways in people living with HIV: a systematic review and meta-analysis.
    Eur Respir J. 2025 May 1:2302174. doi: 10.1183/13993003.02174-2023.
    PubMed     Abstract available
    
    
    February 2025
11. KRAEF C, Roen A, Podlekareva D, Bakowska E, et al
    Incident tuberculosis in people with HIV across Europe from 2012-2022: incidence rates, risk factors, and regional differences in a multicentre cohort study.
    Eur Respir J. 2025 Feb 20:2401904. doi: 10.1183/13993003.01904-2024.
    PubMed     Abstract available
    
    
    January 2025
12. CANGELOSI GA, Salfinger M
    Casting a wider net for tuberculosis cases.
    Eur Respir J. 2025;65:2402245.
    PubMed    
    
    
    
13. WANG Y, Cui J, Li Y, Wang M, et al
    Rapid quantitative PCR on tongue swabs for pulmonary tuberculosis in adults: a prospective multicentre study.
    Eur Respir J. 2025;65:2401493.
    PubMed     Abstract available
    
    
    
14. LOADER MI, Vasquez Alves S, Gilman RH, Coronel J, et al
    Up-regulated matrix metalloproteinase activity in soil-transmitted helminth-tuberculosis co-infection is associated with increased lung pathology.
    Eur Respir J. 2025;65:2401445.
    PubMed     Abstract available
    
    
    December 2024
15. KUNST H, Lange B, Hovardovska O, Bockey A, et al
    Tuberculosis in adult migrants in Europe: a TBnet consensus statement.
    Eur Respir J. 2024 Dec 13:2401612. doi: 10.1183/13993003.01612-2024.
    PubMed     Abstract available
    
    
    November 2024
16. CHHABRA S, Koh MCY, Allen DM
    The treatment of latent tuberculosis infection in migrants in primary care versus secondary care.
    Eur Respir J. 2024;64:2401569.
    PubMed    
    
    
    
17. THU WPP, Loh FK, Ong CWM
    Blood RNA signatures for 8-week sputum tuberculosis culture sterilisation: how close are we?
    Eur Respir J. 2024;64:2401669.
    PubMed    
    
    
    September 2024
18. EDEM VF, Nkereuwem E, Agbla SC, Owusu SA, et al
    Accuracy of Computer-Aided Detection for Tuberculosis (R) on paediatric chest radiographs.
    Eur Respir J. 2024 Sep 3:2400811. doi: 10.1183/13993003.00811-2024.
    PubMed    
    
    
    
19. ROSENHEIM J, Abebe M, Belay M, Tulu B, et al
    Detection of M. tuberculosis DNA in TB contacts' PBMC does not associate with blood RNA signatures for incipient tuberculosis.
    Eur Respir J. 2024 Sep 3:2400479. doi: 10.1183/13993003.00479-2024.
    PubMed    
    
    
    August 2024
20. BURMAN M, Zenner D, Copas AJ, Gosce L, et al
    The treatment of latent tuberculosis infection in migrants in primary care versus secondary care.
    Eur Respir J. 2024 Aug 22:2301733. doi: 10.1183/13993003.01733-2023.
    PubMed     Abstract available
    
    
    
21. GREENAN-BARRETT J, Gupta RK, Noursadeghi M
    The end of the road for blood RNA biomarkers as triage tests for symptomatic pulmonary tuberculosis among spontaneous sputum producers?
    Eur Respir J. 2024;64:2401365.
    PubMed    
    
    
    
22. MUWANGA VM, Mendelsohn SC, Leukes V, Stanley K, et al
    Blood transcriptomic signatures for symptomatic tuberculosis in an African multicohort study.
    Eur Respir J. 2024;64:2400153.
    PubMed     Abstract available
    
    
    
23. CALDERWOOD CJ, Sanchez Martinez A, Greenan-Barrett J, Turner CT, et al
    Resolution of tuberculosis blood RNA signatures fails to discriminate persistent sputum culture positivity after eight weeks of anti-tuberculous treatment.
    Eur Respir J. 2024 Aug 1:2400457. doi: 10.1183/13993003.00457-2024.
    PubMed     Abstract available
    
    
    July 2024
24. KOSER CU, Miotto P, Ismail N, Anthony RM, et al
    A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for Mycobacterium tuberculosis complex.
    Eur Respir J. 2024;64:2400391.
    PubMed     Abstract available
    
    
    June 2024
25. JANKOVIC MAKEK M, Lovric Makaric Z, Petrovic G, Sarajlic G, et al
    New priorities for Croatia to pursue tuberculosis pre-elimination.
    Eur Respir J. 2024;63:2400279.
    PubMed    
    
    
    May 2024
26. GRAY DM, Githinji L, Brittain K, Franckling-Smith Z, et al
    Lung function trajectories in South African children with pulmonary tuberculosis (TB) compared to those with non-TB lower respiratory tract infection: A prospective study.
    Eur Respir J. 2024 May 23:2400216. doi: 10.1183/13993003.00216-2024.
    PubMed    
    
    
    
27. MESIC A, Decuyper I, Ishaq S, Azizi T, et al
    Short oral treatment regimens for rifampicin-resistant tuberculosis are safe and effective for young children: results from a field-based non-randomized clinical trial, Kandahar Afghanistan.
    Eur Respir J. 2024 May 23:2400436. doi: 10.1183/13993003.00436-2024.
    PubMed    
    
    
    April 2024
28. TRAUTH J, Kantelhardt V, Usenko B, Knipper M, et al
    Bedaquiline, pretomanid, and linezolid in multidrug-resistant and pre-extensively drug-resistant tuberculosis in refugees from Ukraine and Somalia in Germany.
    Eur Respir J. 2024 Apr 18:2400303. doi: 10.1183/13993003.00303-2024.
    PubMed    
    
    
    
29. NOGUERA-JULIAN A, Latre C, Flores A
    Availability of paediatric dispersible fixed-dose combinations of tuberculosis drugs in Spain.
    Eur Respir J. 2024;63:2400104.
    PubMed    
    
    
    January 2024
30. ALI M, El Hafid M, Farrar DS, Kourdi H, et al
    Travel-acquired paediatric tuberculosis in the Greater Toronto Area, Canada, 2002-2018.
    Eur Respir J. 2024 Jan 11:2301533. doi: 10.1183/13993003.01533-2023.
    PubMed    
    
    
    
31. 
    "Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update." S. Ghosh, L. Breitscheidel, N. Lazarevic, et al. Eur Respir J 2021; 57: 2002483.
    Eur Respir J. 2024;63:2052483.
    PubMed    
    
    
    November 2023
32. ACHAR J, Seddon JA, Knight GM, Dodd PJ, et al
    Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing.
    Eur Respir J. 2023 Nov 9:2300969. doi: 10.1183/13993003.00969-2023.
    PubMed    
    
    
    
33. PERUMAL R, Bionghi N, Nimmo C, Letsoalo M, et al
    Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: A systematic review and meta-analysis.
    Eur Respir J. 2023 Nov 9:2300639. doi: 10.1183/13993003.00639-2023.
    PubMed    
    
    
    
34. ZENNER D, Cobelens F, Abubakar I
    Reply: Tuberculosis screening in migrants to the EU/EEA and UK.
    Eur Respir J. 2023;62:2301535.
    PubMed    
    
    
    
35. KOHLER N, Vasiliu A, Mandalakas AM, Martinez L, et al
    Tuberculosis screening in migrants to the EU/EEA and UK.
    Eur Respir J. 2023;62:2301230.
    PubMed    
    
    
    
36. DIEL R, Schluger NW
    Long-term outcome of co-infection of COVID-19 and tuberculosis: the "cursed duet".
    Eur Respir J. 2023;62:2301881.
    PubMed    
    
    
    
37. CASCO N, Jorge AL, Palmero DJ, Alffenaar JW, et al
    Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.
    Eur Respir J. 2023;62:2300925.
    PubMed     Abstract available
    
    
    October 2023
38. DEN BOON S, Yedilbayev A
    Screening for tuberculosis among migrants in Europe: harmonising approaches during a humanitarian crisis?
    Eur Respir J. 2023;62:2301537.
    PubMed    
    
    
    
39. AGUIAR SOARES K, Ehrlich J, Camara M, Chaloub S, et al
    Implementation of WHO guidelines on urine lateral flow LAM testing in high TB/HIV burden African countries.
    Eur Respir J. 2023;62:2300556.
    PubMed    
    
    
    
40. ZENNER D, Brals D, Nederby-Ohd J, Menezes D, et al
    Drivers determining tuberculosis disease screening yield in four European screening programmes: a comparative analysis.
    Eur Respir J. 2023;62:2202396.
    PubMed     Abstract available
    
    
    September 2023
41. RIOU C, du Bruyn E, Kim GHJ, da Costa I, et al
    Derivation of a high-resolution CT-based, semi-automated radiographic score in tuberculosis and its relationship to bacillary load and antitubercular therapy.
    Eur Respir J. 2023 Sep 7:2300600. doi: 10.1183/13993003.00600-2023.
    PubMed    
    
    
    
42. BYRNE A, Allwood B, Schoeman I, Johnston J, et al
    "Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials.
    Eur Respir J. 2023;62:2300950.
    PubMed     Abstract available
    
    
    August 2023
43. STOCKER SL, Alffenaar JC
    Predicting early bactericidal activity using pre-clinical data for tuberculosis drugs: a platform for model-informed drug discovery and development.
    Eur Respir J. 2023;62:2301108.
    PubMed    
    
    
    
44. ERNEST JP, Goh JJN, Strydom N, Wang Q, et al
    Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
    Eur Respir J. 2023;62:2300165.
    PubMed     Abstract available
    
    
    June 2023
45. MIGLIORI GB, Dowdy D, Denholm JT, D'Ambrosio L, et al
    The path to tuberculosis elimination: a renewed vision.
    Eur Respir J. 2023;61:2300499.
    PubMed     Abstract available
    
    
    
46. 
    June Podcast: Path to tuberculosis elimination.
    Eur Respir J. 2023;61:23E6106.
    PubMed    
    
    
    May 2023
47. KOSER CU, Maurer FP
    Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for Mycobacterium tuberculosis complex.
    Eur Respir J. 2023;61:2202397.
    PubMed    
    
    
    
48. 
    Reply: Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
    Eur Respir J. 2023;61:2300426.
    PubMed     Abstract available
    
    
    
49. KAHLMETER G, Turnidge J
    The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series.
    Eur Respir J. 2023;61:2202259.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.